Search

Your search keyword '"Lopatin, Yuri"' showing total 41 results
Start Over Author "Lopatin, Yuri" Publisher wiley
41 results on '"Lopatin, Yuri"'

1. Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies

Author

Polovina, Marija, primary, Tschöpe, Carsten, additional, Rosano, Giuseppe, additional, Metra, Marco, additional, Crea, Filippo, additional, Mullens, Wilfried, additional, Bauersachs, Johann, additional, Sliwa, Karen, additional, de Boer, Rudolf A., additional, Farmakis, Dimitrios, additional, Thum, Thomas, additional, Corrado, Domenico, additional, Bayes‐Genis, Antoni, additional, Bozkurt, Biykem, additional, Filippatos, Gerasimos, additional, Keren, Andre, additional, Skouri, Hadi, additional, Moura, Brenda, additional, Volterrani, Maurizio, additional, Abdelhamid, Magdy, additional, Ašanin, Milika, additional, Krljanac, Gordana, additional, Tomić, Milenko, additional, Savarese, Gianluigi, additional, Adamo, Marianna, additional, Lopatin, Yuri, additional, Chioncel, Ovidiu, additional, Coats, Andrew J.S., additional, and Seferović, Petar M., additional

Published
2023
Full Text
View/download PDF

2. State‐of‐the‐art document on optimal contemporary management of cardiomyopathies

Author

Seferović, Petar M., primary, Polovina, Marija, additional, Rosano, Giuseppe, additional, Bozkurt, Biykem, additional, Metra, Marco, additional, Heymans, Stephane, additional, Mullens, Wilfried, additional, Bauersachs, Johann, additional, Sliwa, Karen, additional, de Boer, Rudolf A., additional, Farmakis, Dimitrios, additional, Thum, Thomas, additional, Olivotto, Iacopo, additional, Rapezzi, Claudio, additional, Linhart, Aleš, additional, Corrado, Domenico, additional, Tschöpe, Carsten, additional, Milinković, Ivan, additional, Bayes Genis, Antoni, additional, Filippatos, Gerasimos, additional, Keren, Andre, additional, Ašanin, Milika, additional, Krljanac, Gordana, additional, Maksimović, Ružica, additional, Skouri, Hadi, additional, Ben Gal, Tuvia, additional, Moura, Brenda, additional, Volterrani, Maurizio, additional, Abdelhamid, Magdy, additional, Lopatin, Yuri, additional, Chioncel, Ovidiu, additional, and Coats, Andrew J.S., additional

Published
2023
Full Text
View/download PDF

3. Pre‐discharge and early post‐discharge management of patients hospitalized for acute heart failure: a scientific statement by the Heart Failure Association ( HFA ) of the ESC

Author

Metra, Marco, primary, Adamo, Marianna, additional, Tomasoni, Daniela, additional, Mebazaa, Alexandre, additional, Bayes‐Genis, Antoni, additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Bauersachs, Johann, additional, Belenkov, Yuri, additional, Böhm, Michael, additional, Gal, Tuvia Ben, additional, Butler, Javed, additional, Cohen‐Solal, Alain, additional, Filippatos, Gerasimos, additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Jankowska, Ewa A., additional, Lainscak, Mitja, additional, Lopatin, Yuri, additional, Lund, Lars, additional, McDonagh, Theresa, additional, Milicic, Davor, additional, Moura, Brenda, additional, Mullens, Wilfried, additional, Piepoli, Massimo, additional, Polovina, Marija, additional, Ponikowski, Piotr, additional, Rakisheva, Amina, additional, Ristic, Arsen, additional, Savarese, Gianluigi, additional, Seferovic, Petar, additional, Sharma, Rajan, additional, Thum, Thomas, additional, Tocchetti, Carlo G., additional, Van Linthout, Sophie, additional, Vitale, Cristiana, additional, Von Haehling, Stephan, additional, Volterrani, Maurizio, additional, Coats, Andrew JS, additional, Chioncel, Ovidiu, additional, and Rosano, Giuseppe, additional

Published
2023
Full Text
View/download PDF

4. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC

Author

Metra, Marco, Adamo, Marianna, Tomasoni, Daniela, Mebazaa, Alexandre, Bayes-Genis, Antoni, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Bauersachs, Johann, Belenkov, Yuri, Boehm, Michael, Gal, Tuvia Ben, Butler, Javed, Cohen-Solal, Alain, Filippatos, Gerasimos, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa A., Lainscak, Mitja, Lopatin, Yuri, Lund, Lars H., McDonagh, Theresa, Milicic, Davor, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo, Polovina, Marija, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Seferovic, Petar, Sharma, Rajan, Thum, Thomas, Tocchetti, Carlo G., Van Linthout, Sophie, Vitale, Cristiana, Von Haehling, Stephan, Volterrani, Maurizio, Coats, Andrew J. S., Chioncel, Ovidiu, Rosano, Giuseppe, Metra, Marco, Adamo, Marianna, Tomasoni, Daniela, Mebazaa, Alexandre, Bayes-Genis, Antoni, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Bauersachs, Johann, Belenkov, Yuri, Boehm, Michael, Gal, Tuvia Ben, Butler, Javed, Cohen-Solal, Alain, Filippatos, Gerasimos, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa A., Lainscak, Mitja, Lopatin, Yuri, Lund, Lars H., McDonagh, Theresa, Milicic, Davor, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo, Polovina, Marija, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Seferovic, Petar, Sharma, Rajan, Thum, Thomas, Tocchetti, Carlo G., Van Linthout, Sophie, Vitale, Cristiana, Von Haehling, Stephan, Volterrani, Maurizio, Coats, Andrew J. S., Chioncel, Ovidiu, and Rosano, Giuseppe

Abstract

Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked increases in death and rehospitalization rates, which then decline exponentially though they remain higher than in patients without a recent hospitalization. Therefore, optimal management of patients with acute heart failure before discharge and in the early post-discharge phase is critical. First, it may prevent rehospitalizations through the early detection and effective treatment of residual or recurrent congestion, the main manifestation of decompensation. Second, initiation at pre-discharge and titration to target doses in the early post-discharge period, of guideline-directed medical therapy may improve both short- and long-term outcomes. Third, in chronic heart failure, medical treatment is often left unchanged, so the acute heart failure hospitalization presents an opportunity for implementation of therapy. The aim of this scientific statement by the Heart Failure Association of the European Society of Cardiology is to summarize recent findings that have implications for clinical management both in the pre-discharge and the early post-discharge phase after a hospitalization for acute heart failure.

Published
2023
Full Text
View/download PDF

5. Cardiac remodelling part 2: clinical, imaging and laboratory findings: a review from the Biomarkers Working Group of the Heart Failure Association of the ESC

Author

Aimo, Alberto, Vergaro, Giuseppe, González, Arantxa, Barison, Andrea, Lupón, Josep, Delgado, Victoria, Richards, A Mark, de Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, Hülsmann, Martin, Falcao‐Pires, Inês, Díez, Javier, Foo, Roger SY, Chan, Mark Yan Yee, Anene‐Nzelu, George C, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Belenkov, Yuri, Gal, Tuvia B, Cohen‐Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L, Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H, Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F, Rakisheva, Amina, Ristic, Arsen, Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G, van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew JS, Emdin, Michele, Bayes‐Genis, Antoni, Aimo, Alberto, Vergaro, Giuseppe, González, Arantxa, Barison, Andrea, Lupón, Josep, Delgado, Victoria, Richards, A Mark, de Boer, Rudolf A, Thum, Thoma, Arfsten, Henrike, Hülsmann, Martin, Falcao-Pires, Inê, Díez, Javier, Foo, Roger Sy, Chan, Mark Yan Yee, Anene-Nzelu, George C, Abdelhamid, Magdy, Adamopoulos, Stamati, Anker, Stefan D, Belenkov, Yuri, Gal, Tuvia B, Cohen-Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L, Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H, Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F, Rakisheva, Amina, Ristic, Arsen, Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G, van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J, Emdin, Michele, and Bayes-Genis, Antoni

Subjects
therapies, biomarker, heart failure, imaging, predictor, remodelling, ejection fraction, clinical
Abstract

In patients with heart failure (HF), the beneficial effects of drug and device therapies counteract to some extent ongoing cardiac damage. According to the net balance between these two factors, cardiac geometry and function may improve (reverse remodelling, RR) and even completely normalize (remission), or vice versa progressively deteriorate (adverse remodelling, AR). RR or remission predict a better prognosis, while AR has been associated with worsening clinical status and outcomes. The remodelling process ultimately involves all cardiac chambers, but has been traditionally evaluated in terms of left ventricular volumes and ejection fraction. This is the second part of a review paper by the Biomarker Study Group of the Heart Failure Association of the European Society of Cardiology dedicated to ventricular remodelling. This document examines the proposed criteria to diagnose RR and AR, their prevalence and prognostic value, and the variables predicting remodelling in patients managed according to current guidelines. Much attention will be devoted to RR in patients with HFrEF because most studies on cardiac remodelling focused on this setting.

Published
2022

6. Heart failure during the COVID‐19 pandemic: clinical, diagnostic, management, and organizational dilemmas

Author

Palazzuoli, Alberto, primary, Metra, Marco, additional, Collins, Sean P., additional, Adamo, Marianna, additional, Ambrosy, Andrew P., additional, Antohi, Laura E., additional, Ben Gal, Tuvia, additional, Farmakis, Dimitrios, additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Lopatin, Yuri, additional, Tramonte, Francesco, additional, Lyon, Alexander, additional, Masip, Josep, additional, Miro, Oscar, additional, Moura, Brenda, additional, Mullens, Wilfried, additional, Radu, Razvan I., additional, Abdelhamid, Magdy, additional, Anker, Stefan, additional, and Chioncel, Ovidiu, additional

Published
2022
Full Text
View/download PDF

7. Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology

Author

Núñez, Julio, primary, de la Espriella, Rafael, additional, Rossignol, Patrick, additional, Voors, Adriaan A., additional, Mullens, Wilfried, additional, Metra, Marco, additional, Chioncel, Ovidiu, additional, Januzzi, James L., additional, Mueller, Christian, additional, Richards, A. Mark, additional, de Boer, Rudolf A., additional, Thum, Thomas, additional, Arfsten, Henrike, additional, González, Arantxa, additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Gal, Tuvia Ben, additional, Biegus, Jan, additional, Cohen‐Solal, Alain, additional, Böhm, Michael, additional, Emdin, Michele, additional, Jankowska, Ewa A., additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Jhund, Pardeep S., additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Milicic, Davor, additional, Moura, Brenda, additional, Piepoli, Massimo F., additional, Ponikowski, Piotr, additional, Rakisheva, Amina, additional, Ristic, Arsen, additional, Savarese, Gianluigi, additional, Tocchetti, Carlo G., additional, Van Linthout, Sophie, additional, Volterrani, Maurizio, additional, Seferovic, Petar, additional, Rosano, Giuseppe, additional, Coats, Andrew J.S., additional, and Bayes‐Genis, Antoni, additional

Published
2022
Full Text
View/download PDF

8. Impact analysis of heart failure across European countries: an ESC‐HFA position paper

Author

Rosano, Giuseppe M.C., primary, Seferovic, Petar, additional, Savarese, Gianluigi, additional, Spoletini, Ilaria, additional, Lopatin, Yuri, additional, Gustafsson, Fin, additional, Bayes‐Genis, Antoni, additional, Jaarsma, Tiny, additional, Abdelhamid, Magdy, additional, Miqueo, Arantxa Gonzalez, additional, Piepoli, Massimo, additional, Tocchetti, Carlo G., additional, Ristić, Arsen D., additional, Jankowska, Ewa, additional, Moura, Brenda, additional, Hill, Loreena, additional, Filippatos, Gerasimos, additional, Metra, Marco, additional, Milicic, Davor, additional, Thum, Thomas, additional, Chioncel, Ovidiu, additional, Ben Gal, Tuvia, additional, Lund, Lars H., additional, Farmakis, Dimitrios, additional, Mullens, Wilfried, additional, Adamopoulos, Stamatis, additional, Bohm, Michael, additional, Norhammar, Anna, additional, Bollmann, Andreas, additional, Banerjee, Amitava, additional, Maggioni, Aldo P., additional, Voors, Adriaan, additional, Solal, Alain Cohen, additional, and Coats, Andrew J.S., additional

Published
2022
Full Text
View/download PDF

9. Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology

Author

Seferović, Peter, primary, Farmakis, Dimitrios, additional, Bayes‐Genis, Antoni, additional, Ben Gal, Tuvia, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Ferrari, Roberto, additional, Filippatos, Gerasimos, additional, Hill, Loreena, additional, Jankowska, Ewa, additional, Lainscak, Mitja, additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Mebazaa, Alexandre, additional, Metra, Marco, additional, Moura, Brenda, additional, Rosano, Giuseppe, additional, Thum, Thomas, additional, Voors, Adriaan, additional, and Coats, Andrew J.S., additional

Published
2022
Full Text
View/download PDF

10. Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology

Author

Nunez, Julio, de la Espriella, Rafael, Rossignol, Patrick, Voors, Adriaan A., Mullens, Wilfried, Metra, Marco, Chioncel, Ovidiu, Januzzi, James L., Mueller, Christian, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Gonzalez, Arantxa, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Gal, Tuvia Ben, Biegus, Jan, Cohen-Solal, Alain, Boehm, Michael, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Milicic, Davor, Moura, Brenda, Piepoli, Massimo F., Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Bayes-Genis, Antoni, Nunez, Julio, de la Espriella, Rafael, Rossignol, Patrick, Voors, Adriaan A., Mullens, Wilfried, Metra, Marco, Chioncel, Ovidiu, Januzzi, James L., Mueller, Christian, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Gonzalez, Arantxa, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Gal, Tuvia Ben, Biegus, Jan, Cohen-Solal, Alain, Boehm, Michael, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Milicic, Davor, Moura, Brenda, Piepoli, Massimo F., Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., and Bayes-Genis, Antoni

Abstract

Congestion is a cardinal sign of heart failure (HF). In the past, it was seen as a homogeneous epiphenomenon that identified patients with advanced HF. However, current evidence shows that congestion in HF varies in quantity and distribution. This updated view advocates for a congestive-driven classification of HF according to onset (acute vs. chronic), regional distribution (systemic vs. pulmonary), compartment of distribution (intravascular vs. extravascular), and clinical vs. subclinical. Thus, this review will focus on the utility of circulating biomarkers for assessing and managing the different fluid overload phenotypes. This discussion focused on the clinical utility of the natriuretic peptides, carbohydrate antigen 125 (also called mucin 16), bio-adrenomedullin and mid-regional pro-adrenomedullin, ST2 (also known as interleukin-1 receptor-like 1), cluster of differentiation 146, troponin, C-terminal pro-endothelin-1, and parameters of haemoconcentration. The utility of circulation biomarkers on top of clinical evaluation, haemodynamics, and imaging needs to be better determined by dedicated studies. Some multiparametric frameworks in which these tools contribute to management are proposed., Funding Agencies|Ministry of Economy and Competitiveness; Instituto Carlos III [PI20/00392]; CIBER Cardiovascular [16/11/00420, 16/11/00403]

Published
2022
Full Text
View/download PDF

11. Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author

Gonzalez, Arantxa, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hulsmann, Martin, Falcao-Pires, Ines, Diez, Javier, Foo, Roger S. Y., Chan, Mark Y., Aimo, Alberto, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Boehm, Michael, Chioncel, Ovidiu, Delgado, Victoria, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Nunez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristic, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Bayes-Genis, Antoni, Gonzalez, Arantxa, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hulsmann, Martin, Falcao-Pires, Ines, Diez, Javier, Foo, Roger S. Y., Chan, Mark Y., Aimo, Alberto, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Boehm, Michael, Chioncel, Ovidiu, Delgado, Victoria, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Nunez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristic, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., and Bayes-Genis, Antoni

Abstract

Cardiac remodelling refers to changes in left ventricular structure and function over time, with a progressive deterioration that may lead to heart failure (HF) development (adverse remodelling) or vice versa a recovery (reverse remodelling) in response to HF treatment. Adverse remodelling predicts a worse outcome, whilst reverse remodelling predicts a better prognosis. The geometry, systolic and diastolic function and electric activity of the left ventricle are affected, as well as the left atrium and on the long term even right heart chambers. At a cellular and molecular level, remodelling involves all components of cardiac tissue: cardiomyocytes, fibroblasts, endothelial cells and leucocytes. The molecular, cellular and histological signatures of remodelling may differ according to the cause and severity of cardiac damage, and clearly to the global trend toward worsening or recovery. These processes cannot be routinely evaluated through endomyocardial biopsies, but may be reflected by circulating levels of several biomarkers. Different classes of biomarkers (e.g. proteins, non-coding RNAs, metabolites and/or epigenetic modifications) and several biomarkers of each class might inform on some aspects on HF development, progression and long-term outcomes, but most have failed to enter clinical practice. This may be due to the biological complexity of remodelling, so that no single biomarker could provide great insight on remodelling when assessed alone. Another possible reason is a still incomplete understanding of the role of biomarkers in the pathophysiology of cardiac remodelling. Such role will be investigated in the first part of this review paper on biomarkers of cardiac remodelling., Funding Agencies|Spanish Ministry of Science, Innovation and Universities Institute of Health Carlos III (ISCIII) [PI18/01469, PI21/00946, CB16/11/00403, CB16/11/00483]; European Regional Development FundsEuropean Commission; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [2019-848109-2]; European Research CouncilEuropean Research Council (ERC)European Commission [ERC CoG 818715]; ERC-PoC Megfib; National Medical Research Council of Singapore (NMRC)National Medical Research Council, Singapore [NMRC/STaR/0022/2014, MOH-000280]; Health Research Council of New ZealandHealth Research Council of New Zealand [02/152, 08/070, 11/1070]; National Heart Foundation of New Zealand; New Zealand Lotteries Grant Board; Foundation for Research, Science and TechnologyNew Zealand Foundation for Research, Science and Technology; Christchurch Heart Institute Trust; Netherlands Heart FoundationNetherlands Heart Foundation [2017-21, 2017-11, 2018-30, 2020B005]; leDucq FoundationLeducq Foundation; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [KFO311, TRR267, TTR 219, TRR 1470]; Karolinska Institutet, the Swedish Research CouncilSwedish Research Council [523-2014-2336]; Swedish Heart Lung FoundationSwedish Heart-Lung Foundation [20150557, 20190310]; Stockholm County CouncilStockholm County Council [20170112, 20190525]

Published
2022
Full Text
View/download PDF

12. Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author

Aimo, Alberto, Vergaro, Giuseppe, Gonzalez, Arantxa, Barison, Andrea, Lupon, Josep, Delgado, Victoria, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hulsmann, Martin, Falcao-Pires, Ines, Diez, Javier, Foo, Roger S. Y., Chan, Mark Yan Yee, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Bohm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Nunez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristic, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Emdin, Michele, Bayes-Genis, Antoni, Aimo, Alberto, Vergaro, Giuseppe, Gonzalez, Arantxa, Barison, Andrea, Lupon, Josep, Delgado, Victoria, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hulsmann, Martin, Falcao-Pires, Ines, Diez, Javier, Foo, Roger S. Y., Chan, Mark Yan Yee, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Bohm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Nunez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristic, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Emdin, Michele, and Bayes-Genis, Antoni

Abstract

In patients with heart failure, the beneficial effects of drug and device therapies counteract to some extent ongoing cardiac damage. According to the net balance between these two factors, cardiac geometry and function may improve (reverse remodelling, RR) and even completely normalize (remission), or vice versa progressively deteriorate (adverse remodelling, AR). RR or remission predict a better prognosis, while AR has been associated with worsening clinical status and outcomes. The remodelling process ultimately involves all cardiac chambers, but has been traditionally evaluated in terms of left ventricular volumes and ejection fraction. This is the second part of a review paper by the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology dedicated to ventricular remodelling. This document examines the proposed criteria to diagnose RR and AR, their prevalence and prognostic value, and the variables predicting remodelling in patients managed according to current guidelines. Much attention will be devoted to RR in patients with heart failure with reduced ejection fraction because most studies on cardiac remodelling focused on this setting.

Published
2022
Full Text
View/download PDF

13. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology

Author

Piepoli, Massimo F., Adamo, Marianna, Barison, Andrea, Bestetti, Reinaldo B., Biegus, Jan, Boehm, Michael, Butler, Javed, Carapetis, Jonathan, Ceconi, Claudio, Chioncel, Ovidiu, Coats, Andrew, Crespo-Leiro, Maria G., de Simone, Giovanni, Drexel, Heinz, Emdin, Michele, Farmakis, Dimitros, Halle, Martin, Heymans, Stephane, Jaarsma, Tiny, Jankowska, Ewa, Lainscak, Mitja, Lam, Carolyn S. P., Lochen, Maja-Lisa, Lopatin, Yuri, Maggioni, Aldo, Matrone, Benedetta, Metra, Marco, Noonan, Katharine, Pina, Ileana, Prescott, Eva, Rosano, Giuseppe, Seferovic, Petar M., Sliwa, Karen, Stewart, Simon, Uijl, Alicia, Vaartjes, Ilonca, Vermeulen, Roel, Verschuren, W. M. Monique, Volterrani, Maurizio, von Haehling, Stephan, Hoes, Arno, Piepoli, Massimo F., Adamo, Marianna, Barison, Andrea, Bestetti, Reinaldo B., Biegus, Jan, Boehm, Michael, Butler, Javed, Carapetis, Jonathan, Ceconi, Claudio, Chioncel, Ovidiu, Coats, Andrew, Crespo-Leiro, Maria G., de Simone, Giovanni, Drexel, Heinz, Emdin, Michele, Farmakis, Dimitros, Halle, Martin, Heymans, Stephane, Jaarsma, Tiny, Jankowska, Ewa, Lainscak, Mitja, Lam, Carolyn S. P., Lochen, Maja-Lisa, Lopatin, Yuri, Maggioni, Aldo, Matrone, Benedetta, Metra, Marco, Noonan, Katharine, Pina, Ileana, Prescott, Eva, Rosano, Giuseppe, Seferovic, Petar M., Sliwa, Karen, Stewart, Simon, Uijl, Alicia, Vaartjes, Ilonca, Vermeulen, Roel, Verschuren, W. M. Monique, Volterrani, Maurizio, von Haehling, Stephan, and Hoes, Arno

Abstract

The heart failure epidemic is growing and its prevention, in order to reduce associated hospital readmission rates and its clinical and economic burden, is a key issue in modern cardiovascular medicine. The present position paper aims to provide practical evidence-based information to support the implementation of effective preventive measures. After reviewing the most common risk factors, an overview of the population attributable risks in different continents is presented, to identify potentially effective opportunities for prevention and to inform preventive strategies. Finally, potential interventions that have been proposed and have been shown to be effective in preventing heart failure are listed.

Published
2022
Full Text
View/download PDF

14. Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author

Aimo, Alberto, primary, Vergaro, Giuseppe, additional, González, Arantxa, additional, Barison, Andrea, additional, Lupón, Josep, additional, Delgado, Victoria, additional, Richards, A Mark, additional, de Boer, Rudolf A., additional, Thum, Thomas, additional, Arfsten, Henrike, additional, Hülsmann, Martin, additional, Falcao‐Pires, Inês, additional, Díez, Javier, additional, Foo, Roger S.Y., additional, Chan, Mark Yan Yee, additional, Anene‐Nzelu, Chukwuemeka G., additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Belenkov, Yuri, additional, Ben Gal, Tuvia, additional, Cohen‐Solal, Alain, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Jankowska, Ewa A., additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Januzzi, James L., additional, Jhund, Pardeep, additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Metra, Marco, additional, Milicic, Davor, additional, Moura, Brenda, additional, Mueller, Christian, additional, Mullens, Wilfried, additional, Núñez, Julio, additional, Piepoli, Massimo F., additional, Rakisheva, Amina, additional, Ristić, Arsen D., additional, Rossignol, Patrick, additional, Savarese, Gianluigi, additional, Tocchetti, Carlo G., additional, van Linthout, Sophie, additional, Volterrani, Maurizio, additional, Seferovic, Petar, additional, Rosano, Giuseppe, additional, Coats, Andrew J.S., additional, Emdin, Michele, additional, and Bayes‐Genis, Antoni, additional

Published
2022
Full Text
View/download PDF

15. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author

González, Arantxa, primary, Richards, A. Mark, additional, de Boer, Rudolf A., additional, Thum, Thomas, additional, Arfsten, Henrike, additional, Hülsmann, Martin, additional, Falcao‐Pires, Inês, additional, Díez, Javier, additional, Foo, Roger S.Y., additional, Chan, Mark Y., additional, Aimo, Alberto, additional, Anene‐Nzelu, Chukwuemeka G., additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Belenkov, Yuri, additional, Ben Gal, Tuvia, additional, Cohen‐Solal, Alain, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Delgado, Victoria, additional, Emdin, Michele, additional, Jankowska, Ewa A., additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Januzzi, James L., additional, Jhund, Pardeep S., additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Metra, Marco, additional, Milicic, Davor, additional, Moura, Brenda, additional, Mueller, Christian, additional, Mullens, Wilfried, additional, Núñez, Julio, additional, Piepoli, Massimo F., additional, Rakisheva, Amina, additional, Ristić, Arsen D., additional, Rossignol, Patrick, additional, Savarese, Gianluigi, additional, Tocchetti, Carlo G., additional, Van Linthout, Sophie, additional, Volterrani, Maurizio, additional, Seferovic, Petar, additional, Rosano, Giuseppe, additional, Coats, Andrew J.S., additional, and Bayés‐Genís, Antoni, additional

Published
2022
Full Text
View/download PDF

16. Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology

Author

Mullens, Wilfried, Coats, Andrew J.S., Seferović, Petar M., Metra, Marco I., Mebazaa, Alexandre, Ruschitzka, Frank T., Filippatos, Gerasimos S., Volterrani, Maurizio, Ponikowski, Piotr P., Jankowska, Ewa Anita, Chioncel, Ovidiu, McDonagh, Theresa A., Piepoli, Massimo F., Milicic, Davor, Thum, Thomas, Hill, Loreena Michelle, Abdelhamid, Magdy, Adamopoulos, Stamatis, Belenkov, Yuri, Ben-Gal, Tuvia, Böhm, Michael, Cohen-Solal, Alain, Gustafsson, Finn, Jaarsma, Tiny, Moura, Brenda, Rakisheva, Amina, Ristic, Arsen D., Bayes-Genis, Antonio, Van Linthout, Sophia, Anker, Stefan D., Tocchetti, Carlo Gabriele, Lopatin, Yuri, Lund, Lars, Savarese, Gianluigi, Čelutkienė, Jelena, Cowie, Martin, Lambrinou, Ekaterini, Ray, Robin, Lainscak, Mitja, Skouri, Hadi, Wallner, Markus, Rosano, Giuseppe M C, Mullens, Wilfried, Coats, Andrew, Seferovic, Petar, Metra, Marco, Mebazaa, Alexandre, Ruschitzka, Frank, Filippatos, Gerasimo, Volterrani, Maurizio, Ponikowski, Piotr, Jankowska, Ewa A, Chioncel, Ovidiu, Mcdonagh, Theresa A, Piepoli, Massimo F, Milicic, Davor, Thum, Thoma, Hill, Loreena, Abdelhamid, Magdy, Adamopoulos, Stamati, Belenkov, Yuri, Gal, Tuvia Ben, Böhm, Michael, Cohen-Solal, Alain, Gustafsson, Finn, Jaarsma, Tiny, Moura, Brenda, Rakisheva, Amina, Ristic, Arsen, Bayes-Genis, Antonio, Van Linthout, Sophia, Anker, Stefan D, Tocchetti, Carlo Gabriele, Lopatin, Yury, Lund, Lar, Savarese, Gianluigi, Čelutkienė, Jelena, Cowie, Martin, Lambrinou, Ekaterini, Ray, Robin, Lainscak, Mitja, Skouri, Hadi, Wallner, Marku, and Rosano, Giuseppe M C

Subjects
Heart Failure, Certification, Europe, Humans, Societies, Medical, Cardiology, Quality of patient-centred, Heart failure, Medical and Health Sciences, Comprehensive educational programme, Medical, Quality of care centres, Clinical Medicine, Societies
Abstract

Heart failure (HF) is a devastating chronic and disabling disease with a wide variety of pharmaceutical and device treatment options which are becoming increasingly complex to implement. According to the Heart Failure Association (HFA) Atlas, a subspeciality resource aimed at sourcing contemporary data concerning the epidemiology and healthcare resources for HF, HF is prevalent in17.20 patients per1000 persons, accounting for 2671HFhospitalizations per million inhabitants annually in Europe.1HFpatients also suffer from a high prevalence of non-cardiac comorbidities, which adds complexity to their HF treatment and can negatively impact prognosis.2As a result, HF-related healthcare expenditure continues to rise, and healthcare organizations are becoming faced with the impossible challenge to provide the necessary financial and logistical support to this growing number of patients. In order to address these challenges, the HFA recently outlined the development of quality of care centres (QCC), in order to encourage multidisciplinary management of HF that will improve quality of care and survival.3However, there remains a significant unmet need to train sufficient multidisciplinary teams lead by HF specialists to take care of this expanding group of HF patients. In order to ensure that the next generation of medically-qualified HF specialists will receive high-quality training, this consensus statement of the HFA outlines the requirements for a European training and certification programme for such specialists. The primary goal of this comprehensive educational programme is to increase the quality of patient-centred care related to HF.

Published
2022

17. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology

Author

Piepoli, Massimo F., primary, Adamo, Marianna, additional, Barison, Andrea, additional, Bestetti, Reinaldo B., additional, Biegus, Jan, additional, Böhm, Michael, additional, Butler, Javed, additional, Carapetis, Jonathan, additional, Ceconi, Claudio, additional, Chioncel, Ovidiu, additional, Coats, Andrew, additional, Crespo‐Leiro, Maria G., additional, de Simone, Giovanni, additional, Drexel, Heinz, additional, Emdin, Michele, additional, Farmakis, Dimitros, additional, Halle, Martin, additional, Heymans, Stephane, additional, Jaarsma, Tiny, additional, Jankowska, Ewa, additional, Lainscak, Mitja, additional, Lam, Carolyn S.P., additional, Løchen, Maja‐Lisa, additional, Lopatin, Yuri, additional, Maggioni, Aldo, additional, Matrone, Benedetta, additional, Metra, Marco, additional, Noonan, Katharine, additional, Pina, Ileana, additional, Prescott, Eva, additional, Rosano, Giuseppe, additional, Seferovic, Petar M., additional, Sliwa, Karen, additional, Stewart, Simon, additional, Uijl, Alicia, additional, Vaartjes, Ilonca, additional, Vermeulen, Roel, additional, Monique Verschuren, W. M., additional, Volterrani, Maurizio, additional, von Haehling, Stephan, additional, and Hoes, Arno, additional

Published
2022
Full Text
View/download PDF

18. Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline‐directed medical therapy in heart failure with reduced ejection fraction

Author

Seferović, Petar M., primary, Polovina, Marija, additional, Adlbrecht, Christopher, additional, Bělohlávek, Jan, additional, Chioncel, Ovidiu, additional, Goncalvesová, Eva, additional, Milinković, Ivan, additional, Grupper, Avishay, additional, Halmosi, Róbert, additional, Kamzola, Ginta, additional, Koskinas, Konstantinos C., additional, Lopatin, Yuri, additional, Parkhomenko, Alexander, additional, Põder, Pentti, additional, Ristić, Arsen D., additional, Šakalytė, Gintarė, additional, Trbušić, Matias, additional, Tundybayeva, Meiramgul, additional, Vrtovec, Bojan, additional, Yotov, Yoto T., additional, Miličić, Davor, additional, Ponikowski, Piotr, additional, Metra, Marco, additional, Rosano, Giuseppe, additional, and Coats, Andrew J.S., additional

Published
2021
Full Text
View/download PDF

19. Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature

Author

Radu, Razvan I., primary, Ben Gal, Tuvia, additional, Abdelhamid, Magdy, additional, Antohi, Elena‐Laura, additional, Adamo, Marianna, additional, Ambrosy, Andrew P., additional, Geavlete, Oliviana, additional, Lopatin, Yuri, additional, Lyon, Alexander, additional, Miro, Oscar, additional, Metra, Marco, additional, Parissis, John, additional, Collins, Sean P., additional, Anker, Stefan D., additional, and Chioncel, Ovidiu, additional

Published
2021
Full Text
View/download PDF

20. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology

Author

Jaarsma, Tiny, Hill, Loreena, Bayes-Genis, Antoni, La Rocca, Hans-Peter Brunner, Castiello, Teresa, Celutkiene, Jelena, Marques-Sule, Elena, Plymen, Carla M., Piper, Susan E., Riegel, Barbara, Rutten, Frans H., Ben Gal, Tuvia, Bauersachs, Johann, Coats, Andrew J. S., Chioncel, Ovidiu, Lopatin, Yuri, Lund, Lars H., Lainscak, Mitja, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo F., Rosano, Giuseppe, Seferovic, Petar, Strömberg, Anna, Jaarsma, Tiny, Hill, Loreena, Bayes-Genis, Antoni, La Rocca, Hans-Peter Brunner, Castiello, Teresa, Celutkiene, Jelena, Marques-Sule, Elena, Plymen, Carla M., Piper, Susan E., Riegel, Barbara, Rutten, Frans H., Ben Gal, Tuvia, Bauersachs, Johann, Coats, Andrew J. S., Chioncel, Ovidiu, Lopatin, Yuri, Lund, Lars H., Lainscak, Mitja, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo F., Rosano, Giuseppe, Seferovic, Petar, and Strömberg, Anna

Abstract

Self-care is essential in the long-term management of chronic heart failure. Heart failure guidelines stress the importance of patient education on treatment adherence, lifestyle changes, symptom monitoring and adequate response to possible deterioration. Self-care is related to medical and person-centred outcomes in patients with heart failure such as better quality of life as well as lower mortality and readmission rates. Although guidelines give general direction for self-care advice, health care professionals working with patients with heart failure need more specific recommendations. The aim of the management recommendations in this paper is to provide practical advice for health professionals delivering care to patients with heart failure. Recommendations for nutrition, physical activity, medication adherence, psychological status, sleep, leisure and travel, smoking, immunization and preventing infections, symptom monitoring, and symptom management are consistent with information from guidelines, expert consensus documents, recent evidence and expert opinion.

Published
2021
Full Text
View/download PDF

21. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology

Author

Rosano, Giuseppe M.C., primary, Moura, Brenda, additional, Metra, Marco, additional, Böhm, Michael, additional, Bauersachs, Johann, additional, Ben Gal, Tuvia, additional, Adamopoulos, Stamatis, additional, Abdelhamid, Magdy, additional, Bistola, Vasiliki, additional, Čelutkienė, Jelena, additional, Chioncel, Ovidiu, additional, Farmakis, Dimitrios, additional, Ferrari, Roberto, additional, Filippatos, Gerasimos, additional, Hill, Loreena, additional, Jankowska, Ewa A., additional, Jaarsma, Tiny, additional, Jhund, Pardeep, additional, Lainscak, Mitja, additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Milicic, Davor, additional, Mullens, Wilfried, additional, Pinto, Fausto, additional, Ponikowski, Piotr, additional, Savarese, Gianluigi, additional, Thum, Thomas, additional, Volterrani, Maurizio, additional, Anker, Stefan D., additional, Seferovic, Petar M., additional, and Coats, Andrew J.S., additional

Published
2021
Full Text
View/download PDF

22. Heart Failure Association of the European Society of Cardiology update on sodium glucose co‐transporter‐2 inhibitors in heart failure (an update on the Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology)

Author

Seferović, Petar M., Fragasso, Gabriele, Petrie, Mark, Mullens, Wilfried, Ferrari, Roberto, Thum, Thomas, Bauersachs, Johann, Anker, Stefan D., Ray, Robin, Çavuşoğlu, Yuksel, Polovina, Marija, Metra, Marco, Ambrosio, Giuseppe, Prasad, Krishna, Seferović, Jelena, Jhund, Pardeep S., Dattilo, Giuseppe, Čelutkiene, Jelena, Piepoli, Massimo, Moura, Brenda, Chioncel, Ovidiu, Ben Gal, Tuvia, Heymans, Stephane, Jaarsma, Tiny, Hill, Loreena, Lopatin, Yuri, Lyon, Alexander R., Ponikowski, Piotr, Lainščak, Mitja, Jankowska, Ewa, Mueller, Christian, Cosentino, Francesco, Lund, Lars H., Filippatos, Gerasimos S., Ruschitzka, Frank, Coats, Andrew J.S., and Rosano, Giuseppe M.C.

Abstract

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:\ud \ud Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin have consistently demonstrated to be effective for the prevention of HF hospitalisation in patients with T2DM and established CV disease or at high CV risk. The specifically listed agents are recommended.\ud \ud Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalisation and CV death in symptomatic patients with HF and reduced ejection fraction, already receiving guideline directed medical therapy, regardless of the presence of T2DM.

Published
2020

23. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology

Author

Seferovic, Petar M., Fragasso, Gabriele, Petrie, Mark, Mullens, Wilfried, Ferrari, Roberto, Thum, Thomas, Bauersachs, Johann, Anker, Stefan D., Ray, Robin, Cavusoglu, Yuksel, Polovina, Marija, Metra, Marco, Ambrosio, Giuseppe, Prasad, Krishna, Seferovic, Jelena, Jhund, Pardeep S., Dattilo, Giuseppe, Celutkiene, Jelena, Piepoli, Massimo, Moura, Brenda, Chioncel, Ovidiu, Ben Gal, Tuvia, Heymans, Stefan, de Boer, Rudolf A., Jaarsma, Tiny, Hill, Loreena, Lopatin, Yuri, Lyon, Alexander R., Ponikowski, Piotr, Lainscak, Mitja, Jankowska, Ewa, Mueller, Christian, Cosentino, Francesco, Lund, Lars, Filippatos, Gerasimos S., Ruschitzka, Frank, Coats, Andrew J. S., Rosano, Giuseppe M. C., Seferovic, Petar M., Fragasso, Gabriele, Petrie, Mark, Mullens, Wilfried, Ferrari, Roberto, Thum, Thomas, Bauersachs, Johann, Anker, Stefan D., Ray, Robin, Cavusoglu, Yuksel, Polovina, Marija, Metra, Marco, Ambrosio, Giuseppe, Prasad, Krishna, Seferovic, Jelena, Jhund, Pardeep S., Dattilo, Giuseppe, Celutkiene, Jelena, Piepoli, Massimo, Moura, Brenda, Chioncel, Ovidiu, Ben Gal, Tuvia, Heymans, Stefan, de Boer, Rudolf A., Jaarsma, Tiny, Hill, Loreena, Lopatin, Yuri, Lyon, Alexander R., Ponikowski, Piotr, Lainscak, Mitja, Jankowska, Ewa, Mueller, Christian, Cosentino, Francesco, Lund, Lars, Filippatos, Gerasimos S., Ruschitzka, Frank, Coats, Andrew J. S., and Rosano, Giuseppe M. C.

Abstract

Heart failure (HF) is common and associated with a poor prognosis, despite advances in treatment. Over the last decade cardiovascular outcome trials with sodium-glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus have demonstrated beneficial effects for three SGLT2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) in reducing hospitalisations for HF. More recently, dapagliflozin reduced the risk of worsening HF or death from cardiovascular causes in patients with chronic HF with reduced left ventricular ejection fraction, with or without type 2 diabetes mellitus. A number of additional trials in HF patients with reduced and/or preserved left ventricular ejection fraction are ongoing and/or about to be reported. The present position paper summarises recent clinical trial evidence and discusses the role of SGLT2 inhibitors in the treatment of HF, pending the results of ongoing trials in different populations of patients with HF.

Published
2020
Full Text
View/download PDF

24. Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure (an update on the sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology)

Author

Seferovic, Petar M., Fragasso, Gabriele, Petrie, Mark, Mullens, Wilfried, Ferrari, Roberto, Thum, Thomas, Bauersachs, Johann, Anker, Stefan D., Ray, Robin, Cavusoglu, Yuksel, Polovina, Marija, Metra, Marco, Ambrosio, Giuseppe, Prasad, Krishna, Seferovic, Jelena, Jhund, Pardeep S., Dattilo, Giuseppe, Celutkiene, Jelena, Piepoli, Massimo, Moura, Brenda, Chioncel, Ovidiu, Ben Gal, Tuvia, Heymans, Stephane, Jaarsma, Tiny, Hill, Loreena, Lopatin, Yuri, Lyon, Alexander R., Ponikowski, Piotr, Lainscak, Mitja, Jankowska, Ewa, Mueller, Christian, Cosentino, Francesco, Lund, Lars H., Filippatos, Gerasimos S., Ruschitzka, Frank, Coats, Andrew J. S., Rosano, Giuseppe M. C., Seferovic, Petar M., Fragasso, Gabriele, Petrie, Mark, Mullens, Wilfried, Ferrari, Roberto, Thum, Thomas, Bauersachs, Johann, Anker, Stefan D., Ray, Robin, Cavusoglu, Yuksel, Polovina, Marija, Metra, Marco, Ambrosio, Giuseppe, Prasad, Krishna, Seferovic, Jelena, Jhund, Pardeep S., Dattilo, Giuseppe, Celutkiene, Jelena, Piepoli, Massimo, Moura, Brenda, Chioncel, Ovidiu, Ben Gal, Tuvia, Heymans, Stephane, Jaarsma, Tiny, Hill, Loreena, Lopatin, Yuri, Lyon, Alexander R., Ponikowski, Piotr, Lainscak, Mitja, Jankowska, Ewa, Mueller, Christian, Cosentino, Francesco, Lund, Lars H., Filippatos, Gerasimos S., Ruschitzka, Frank, Coats, Andrew J. S., and Rosano, Giuseppe M. C.

Abstract

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given: center dot Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin have consistently demonstrated to be effective for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. The specifically listed agents are recommended. center dot Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction, already receiving guideline-directed medical therapy, regardless of the presence of type 2 diabetes mellitus.

Published
2020
Full Text
View/download PDF

25. Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document

Author

Seferovic, Petar M., Piepoli, Massimo F., Lopatin, Yuri, Jankowska, Ewa, Polovina, Marija, Anguita-Sanchez, Manuel, Stoerk, Stefan, Lainscak, Mitja, Milicic, Davor, Milinkovic, Ivan, Filippatos, Gerasimos, Coats, Andrew J. S., Seferovic, Petar M., Piepoli, Massimo F., Lopatin, Yuri, Jankowska, Ewa, Polovina, Marija, Anguita-Sanchez, Manuel, Stoerk, Stefan, Lainscak, Mitja, Milicic, Davor, Milinkovic, Ivan, Filippatos, Gerasimos, and Coats, Andrew J. S.

Abstract

Heart failure (HF) is the major contributor to cardiovascular morbidity and mortality. Given its rising prevalence, the costs of HF care can be expected to increase. Multidisciplinary management of HF can improve quality of care and survival. However, specialized HF programmes are not widely available in most European countries. These circumstances underlie the suggestion of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) for the development of quality of care centres (QCCs). These are defined as health care institutions that provide multidisciplinary HF management at all levels of care (primary, secondary and tertiary), are accredited by the HFA/ESC and are implemented into existing health care systems. Their major goals are to unify and improve the quality of HF care, and to promote collaboration in education and research activities. Three types of QCC are suggested: community QCCs (primary care facilities able to provide non-invasive assessment and optimal therapy); specialized QCCs (district hospitals with intensive care units, able to provide cardiac catheterization and device implantation services), and advanced QCCs (national reference centres able to deliver advanced and innovative HF care and research). QCC accreditation will require compliance with general and specific HFA/ESC accreditation standards. General requirements include confirmation of the centres existence, commitment to QCC implementation, and collaboration with other QCCs. Specific requirements include validation of the centres level of care, service portfolio, facilities and equipment, management, human resources, process measures, quality indicators and outcome measures. Audit and recertification at 4-6-year intervals are also required. The implementation of QCCs will evolve gradually, following a pilot phase in selected countries. The present document summarizes the definition, major goals, development, classification and crucial aspects of the accreditation

Published
2020
Full Text
View/download PDF

26. Self‐care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology

Author

Jaarsma, Tiny, primary, Hill, Loreena, additional, Bayes‐Genis, Antoni, additional, La Rocca, Hans‐Peter Brunner, additional, Castiello, Teresa, additional, Čelutkienė, Jelena, additional, Marques‐Sule, Elena, additional, Plymen, Carla M., additional, Piper, Susan E., additional, Riegel, Barbara, additional, Rutten, Frans H., additional, Ben Gal, Tuvia, additional, Bauersachs, Johann, additional, Coats, Andrew J.S., additional, Chioncel, Ovidiu, additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Lainscak, Mitja, additional, Moura, Brenda, additional, Mullens, Wilfried, additional, Piepoli, Massimo F., additional, Rosano, Giuseppe, additional, Seferovic, Petar, additional, and Strömberg, Anna, additional

Published
2020
Full Text
View/download PDF

28. Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology

Author

Seferović, Petar M., primary, Fragasso, Gabriele, additional, Petrie, Mark, additional, Mullens, Wilfried, additional, Ferrari, Roberto, additional, Thum, Thomas, additional, Bauersachs, Johann, additional, Anker, Stefan D., additional, Ray, Robin, additional, Çavuşoğlu, Yuksel, additional, Polovina, Marija, additional, Metra, Marco, additional, Ambrosio, Giuseppe, additional, Prasad, Krishna, additional, Seferović, Jelena, additional, Jhund, Pardeep S., additional, Dattilo, Giuseppe, additional, Čelutkiene, Jelena, additional, Piepoli, Massimo, additional, Moura, Brenda, additional, Chioncel, Ovidiu, additional, Ben Gal, Tuvia, additional, Heymans, Stefan, additional, Boer, Rudolf A., additional, Jaarsma, Tiny, additional, Hill, Loreena, additional, Lopatin, Yuri, additional, Lyon, Alexander R., additional, Ponikowski, Piotr, additional, Lainščak, Mitja, additional, Jankowska, Ewa, additional, Mueller, Christian, additional, Cosentino, Francesco, additional, Lund, Lars, additional, Filippatos, Gerasimos S., additional, Ruschitzka, Frank, additional, Coats, Andrew J.S., additional, and Rosano, Giuseppe M.C., additional

Published
2020
Full Text
View/download PDF

29. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure

Author

Seferović, Petar M., primary, Coats, Andrew J.S., additional, Ponikowski, Piotr, additional, Filippatos, Gerasimos, additional, Huelsmann, Martin, additional, Jhund, Pardeep S., additional, Polovina, Marija M., additional, Komajda, Michel, additional, Seferović, Jelena, additional, Sari, Ibrahim, additional, Cosentino, Francesco, additional, Ambrosio, Giuseppe, additional, Metra, Marco, additional, Piepoli, Massimo, additional, Chioncel, Ovidiu, additional, Lund, Lars H., additional, Thum, Thomas, additional, De Boer, Rudolf A., additional, Mullens, Wilfried, additional, Lopatin, Yuri, additional, Volterrani, Maurizio, additional, Hill, Loreena, additional, Bauersachs, Johann, additional, Lyon, Alexander, additional, Petrie, Mark C., additional, Anker, Stefan, additional, and Rosano, Giuseppe M.C., additional

Published
2020
Full Text
View/download PDF

30. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology

Author

Seferovic, Petar M., Polovina, Marija, Bauersachs, Johann, Arad, Michael, Ben Gal, Tuvia, Lund, Lars H., Felix, Stephan B., Arbustini, Eloisa, Caforio, Alida L. P., Farmakis, Dimitrios, Filippatos, Gerasimos S., Gialafos, Elias, Kanjuh, Vladimir, Krljanac, Gordana, Limongelli, Giuseppe, Linhart, Ales, Lyon, Alexander R., Maksimovic, Ruzica, Milicic, Davor, Milinkovic, Ivan, Noutsias, Michel, Oto, Ali, Oto, Oztekin, Pavlovic, Sinisa U., Piepoli, Massimo F., Ristic, Arsen D., Rosano, Giuseppe M. C., Seggewiss, Hubert, Asanin, Milika, Seferovic, Jelena R., Ruschitzka, Frank, Celutkiene, Jelena, Jaarsma, Tiny, Mueller, Christian, Moura, Brenda, Hill, Loreena, Volterrani, Maurizio, Lopatin, Yuri, Metra, Marco, Backs, Johannes, Mullens, Wilfried, Chioncel, Ovidiu, de Boer, Rudolf A., Anker, Stefan, Rapezzi, Claudio, Coats, Andrew J. s, Tschoepes, Carsten, Seferovic, Petar M., Polovina, Marija, Bauersachs, Johann, Arad, Michael, Ben Gal, Tuvia, Lund, Lars H., Felix, Stephan B., Arbustini, Eloisa, Caforio, Alida L. P., Farmakis, Dimitrios, Filippatos, Gerasimos S., Gialafos, Elias, Kanjuh, Vladimir, Krljanac, Gordana, Limongelli, Giuseppe, Linhart, Ales, Lyon, Alexander R., Maksimovic, Ruzica, Milicic, Davor, Milinkovic, Ivan, Noutsias, Michel, Oto, Ali, Oto, Oztekin, Pavlovic, Sinisa U., Piepoli, Massimo F., Ristic, Arsen D., Rosano, Giuseppe M. C., Seggewiss, Hubert, Asanin, Milika, Seferovic, Jelena R., Ruschitzka, Frank, Celutkiene, Jelena, Jaarsma, Tiny, Mueller, Christian, Moura, Brenda, Hill, Loreena, Volterrani, Maurizio, Lopatin, Yuri, Metra, Marco, Backs, Johannes, Mullens, Wilfried, Chioncel, Ovidiu, de Boer, Rudolf A., Anker, Stefan, Rapezzi, Claudio, Coats, Andrew J. s, and Tschoepes, Carsten

Abstract

Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural history of HF in cardiomyopathies is limited, and distinct features of their therapeutic responses have not been systematically addressed. Therefore, this position paper focuses on epidemiology, pathophysiology, natural history and latest developments in treatment of HF in patients with dilated (DCM), hypertrophic (HCM) and restrictive (RCM) cardiomyopathies. In DCM, HF with reduced ejection fraction (HFrEF) has high incidence and prevalence and represents the most frequent cause of death, despite improvements in treatment. In addition, advanced HF in DCM is one of the leading indications for heart transplantation. In HCM, HF with preserved ejection (HFpEF) affects most patients with obstructive, and similar to 10% of patients with non-obstructive HCM. A timely treatment is important, since development of advanced HF, although rare in HCM, portends a poor prognosis. In RCM, HFpEF is common, while HFrEF occurs later and more frequently in amyloidosis or iron overload/haemochromatosis. Irrespective of RCM aetiology, HF is a harbinger of a poor outcome. Recent advances in our understanding of the mechanisms underlying the development of HF in cardiomyopathies have significant implications for therapeutic decision-making. In addition, new aetiology-specific treatment options (e.g. enzyme replacement therapy, transthyretin stabilizers, immunoadsorption, immunotherapy, etc.) have shown a potential to improve outcomes. Still, causative therapies of many cardiomyopathies are lacking, highlighting the need for the development of effective strategies to prevent and treat HF in cardiomyopathies.

Published
2019
Full Text
View/download PDF

31. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology

Author

Seferović, Petar M., primary, Polovina, Marija, additional, Bauersachs, Johann, additional, Arad, Michael, additional, Ben Gal, Tuvia, additional, Lund, Lars H., additional, Felix, Stephan B., additional, Arbustini, Eloisa, additional, Caforio, Alida L.P., additional, Farmakis, Dimitrios, additional, Filippatos, Gerasimos S., additional, Gialafos, Elias, additional, Kanjuh, Vladimir, additional, Krljanac, Gordana, additional, Limongelli, Giuseppe, additional, Linhart, Aleš, additional, Lyon, Alexander R., additional, Maksimović, Ružica, additional, Miličić, Davor, additional, Milinković, Ivan, additional, Noutsias, Michel, additional, Oto, Ali, additional, Oto, Öztekin, additional, Pavlović, Siniša U., additional, Piepoli, Massimo F., additional, Ristić, Arsen D., additional, Rosano, Giuseppe M.C., additional, Seggewiss, Hubert, additional, Ašanin, Milika, additional, Seferović, Jelena P., additional, Ruschitzka, Frank, additional, Čelutkiene, Jelena, additional, Jaarsma, Tiny, additional, Mueller, Christian, additional, Moura, Brenda, additional, Hill, Loreena, additional, Volterrani, Maurizio, additional, Lopatin, Yuri, additional, Metra, Marco, additional, Backs, Johannes, additional, Mullens, Wilfried, additional, Chioncel, Ovidiu, additional, de Boer, Rudolf A., additional, Anker, Stefan, additional, Rapezzi, Claudio, additional, Coats, Andrew J.S., additional, and Tschöpe, Carsten, additional

Published
2019
Full Text
View/download PDF

32. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology

Author

Seferović, Petar M., primary, Petrie, Mark C., additional, Filippatos, Gerasimos S., additional, Anker, Stefan D., additional, Rosano, Giuseppe, additional, Bauersachs, Johann, additional, Paulus, Walter J., additional, Komajda, Michel, additional, Cosentino, Francesco, additional, de Boer, Rudolf A., additional, Farmakis, Dimitrios, additional, Doehner, Wolfram, additional, Lambrinou, Ekaterini, additional, Lopatin, Yuri, additional, Piepoli, Massimo F., additional, Theodorakis, Michael J., additional, Wiggers, Henrik, additional, Lekakis, John, additional, Mebazaa, Alexandre, additional, Mamas, Mamas A., additional, Tschöpe, Carsten, additional, Hoes, Arno W., additional, Seferović, Jelena P., additional, Logue, Jennifer, additional, McDonagh, Theresa, additional, Riley, Jillian P., additional, Milinković, Ivan, additional, Polovina, Marija, additional, van Veldhuisen, Dirk J., additional, Lainscak, Mitja, additional, Maggioni, Aldo P., additional, Ruschitzka, Frank, additional, and McMurray, John J.V., additional

Published
2018
Full Text
View/download PDF

33. Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology

Author

Julio Núñez, Rafael de la Espriella, Patrick Rossignol, Adriaan A. Voors, Wilfried Mullens, Marco Metra, Ovidiu Chioncel, James L. Januzzi, Christian Mueller, A. Mark Richards, Rudolf A. de Boer, Thomas Thum, Henrike Arfsten, Arantxa González, Magdy Abdelhamid, Stamatis Adamopoulos, Stefan D. Anker, Tuvia Ben Gal, Jan Biegus, Alain Cohen‐Solal, Michael Böhm, Michele Emdin, Ewa A. Jankowska, Finn Gustafsson, Loreena Hill, Tiny Jaarsma, Pardeep S. Jhund, Yuri Lopatin, Lars H. Lund, Davor Milicic, Brenda Moura, Massimo F. Piepoli, Piotr Ponikowski, Amina Rakisheva, Arsen Ristic, Gianluigi Savarese, Carlo G. Tocchetti, Sophie Van Linthout, Maurizio Volterrani, Petar Seferovic, Giuseppe Rosano, Andrew J.S. Coats, Antoni Bayes‐Genis, Publica, Núñez, Julio, de la Espriella, Rafael, Rossignol, Patrick, Voors, Adriaan A, Mullens, Wilfried, Metra, Marco, Chioncel, Ovidiu, Januzzi, James L, Mueller, Christian, Richards, A Mark, de Boer, Rudolf A, Thum, Thoma, Arfsten, Henrike, González, Arantxa, Abdelhamid, Magdy, Adamopoulos, Stamati, Anker, Stefan D, Gal, Tuvia Ben, Biegus, Jan, Cohen-Solal, Alain, Böhm, Michael, Emdin, Michele, Jankowska, Ewa A, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jhund, Pardeep S, Lopatin, Yuri, Lund, Lars H, Milicic, Davor, Moura, Brenda, Piepoli, Massimo F, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Tocchetti, Carlo G, Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J S, and Bayes-Genis, Antoni

Subjects
Heart Failure, Adrenomedullin, Cardiology, Congestion, Humans, Acute heart failure, Biomarker, Prognosis, Cardiology and Cardiovascular Medicine, Biomarkers
Abstract

Congestion is a cardinal sign of heart failure (HF). In the past, it was seen as a homogeneous epiphenomenon that identified patients with advanced HF. However, current evidence shows that congestion in HF varies in quantity and distribution. This updated view advocates for a congestive-driven classification of HF according to onset (acute vs. chronic), regional distribution (systemic vs. pulmonary), compartment of distribution (intravascular vs. extravascular), and clinical vs. subclinical. Thus, this review will focus on the utility of circulating biomarkers for assessing and managing the different fluid overload phenotypes. This discussion focused on the clinical utility of the natriuretic peptides, carbohydrate antigen 125 (also called mucin 16), bio-adrenomedullin and mid-regional pro-adrenomedullin, ST2 (also known as interleukin-1 receptor-like 1), cluster of differentiation 146, troponin, C-terminal pro-endothelin-1, and parameters of haemoconcentration. The utility of circulation biomarkers on top of clinical evaluation, haemodynamics, and imaging needs to be better determined by dedicated studies. Some multiparametric frameworks in which these tools contribute to management are proposed.

Published
2022

34. Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial.

Author

Tromp J, Lam CSP, Alemayehu W, de Filippi CR, Melenovský V, Sliwa K, Lopatin Y, Arango JL, Bahit MC, Roessig L, O'Connor CM, Shah P, Westerhout CM, Voors AA, Pieske B, and Armstrong PW

Subjects
Humans, Female, Male, Middle Aged, Aged, Ventricular Function, Left physiology, Prospective Studies, Heart Failure physiopathology, Stroke Volume physiology, Ventricular Remodeling physiology, Biomarkers, Echocardiography methods
Abstract

Aims: Reverse ventricular remodelling, defined as a decrease in left ventricular end-systolic volume indexed to body surface area (LVESVI) or an increase in left ventricular ejection fraction (LVEF), is associated with improved clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, the underlying pathophysiological mechanisms remain unclear., Methods and Results: We evaluated paired core-lab assessed echocardiograms and measurements of 92 biomarkers at baseline and 8 months thereafter in 419 participants with HFrEF. Reverse ventricular remodelling was defined as a >5% LVEF increase or >15% LVESVI relative decrease between baseline and 8 months. We evaluated the association between baseline biomarkers and their changes with reverse ventricular remodelling in the prospectively randomized controlled VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial. Of 419 patients (median age 66 [interquartile range 57-74] years, 27.4% women), 206 (49.2%) had reverse ventricular remodelling (either a 5% LVEF increase or a 15% LVESVI decrease). There were no differences in baseline biomarker concentrations between patients with versus those without reverse ventricular remodelling on follow-up. However, in patients with reverse ventricular remodelling there were significant decreases in biomarkers relating to inflammation and cardiac metabolism; particularly the tumour necrosis factor superfamily member 13B (ratio 0.82, 95% confidence interval [CI] 0.77-0.88), growth differentiation factor-15 (ratio 0.74, 95% CI 0.66-0.84), and insulin-like growth factor binding protein 7 (ratio 0.80, 95% CI 0.73-0.88)., Conclusions: Reverse ventricular remodelling in patients with HFrEF is associated with a decrease of biomarkers related to inflammation and cardiac metabolism., (© 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

35. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC.

Author

Metra M, Adamo M, Tomasoni D, Mebazaa A, Bayes-Genis A, Abdelhamid M, Adamopoulos S, Anker SD, Bauersachs J, Belenkov Y, Böhm M, Gal TB, Butler J, Cohen-Solal A, Filippatos G, Gustafsson F, Hill L, Jaarsma T, Jankowska EA, Lainscak M, Lopatin Y, Lund LH, McDonagh T, Milicic D, Moura B, Mullens W, Piepoli M, Polovina M, Ponikowski P, Rakisheva A, Ristic A, Savarese G, Seferovic P, Sharma R, Thum T, Tocchetti CG, Van Linthout S, Vitale C, Von Haehling S, Volterrani M, Coats AJS, Chioncel O, and Rosano G

Subjects
Humans, Aftercare, Hospitalization, Patient Readmission, Patient Discharge, Heart Failure drug therapy
Abstract

Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked increases in death and rehospitalization rates, which then decline exponentially though they remain higher than in patients without a recent hospitalization. Therefore, optimal management of patients with acute heart failure before discharge and in the early post-discharge phase is critical. First, it may prevent rehospitalizations through the early detection and effective treatment of residual or recurrent congestion, the main manifestation of decompensation. Second, initiation at pre-discharge and titration to target doses in the early post-discharge period, of guideline-directed medical therapy may improve both short- and long-term outcomes. Third, in chronic heart failure, medical treatment is often left unchanged, so the acute heart failure hospitalization presents an opportunity for implementation of therapy. The aim of this scientific statement by the Heart Failure Association of the European Society of Cardiology is to summarize recent findings that have implications for clinical management both in the pre-discharge and the early post-discharge phase after a hospitalization for acute heart failure., (© 2023 European Society of Cardiology.)

Published
2023
Full Text
View/download PDF

36. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy.

Author

Pieske B, Pieske-Kraigher E, Lam CSP, Melenovský V, Sliwa K, Lopatin Y, Arango JL, Bahit MC, O'Connor CM, Patel MJ, Roessig L, Morris DA, Kropf M, Westerhout CM, Zheng Y, and Armstrong PW

Subjects
Humans, Stroke Volume, Ventricular Function, Left, Echocardiography, Heart Failure diagnostic imaging, Heart Failure drug therapy, Heart Failure chemically induced, Heterocyclic Compounds, 2-Ring
Abstract

Aim: Vericiguat significantly reduced the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death in the VICTORIA trial. It is unknown if these outcome benefits are related to reverse left ventricular (LV) remodelling with vericiguat in patients with HF with reduced ejection fraction (HFrEF). The aim of this study was to compare the effects of vericiguat versus placebo on LV structure and function after 8 months of therapy in patients with HFrEF., Methods and Results: Standardized transthoracic echocardiography (TTE) was performed at baseline and after 8 months of therapy in a subset of HFrEF patients in VICTORIA. The co-primary endpoints were changes in LV end-systolic volume index (LVESVI) and LV ejection fraction (LVEF). Quality assurance and central reading were performed by an echocardiographic core laboratory blinded to treatment assignment. A total of 419 patients (208 vericiguat, 211 placebo) with high-quality paired TTE at baseline and 8 months were included. Baseline clinical characteristics were well balanced between treatment groups and echocardiographic characteristics were representative of patients with HFrEF. LVESVI significantly declined (60.7 ± 26.8 to 56.8 ± 30.4 ml/m 2 ; p < 0.01) and LVEF significantly increased (33.0 ± 9.4% to 36.1 ± 10.2%; p < 0.01) in the vericiguat group, but similarly in the placebo group (absolute changes for vericiguat vs. placebo: LVESVI -3.8 ± 15.4 vs. -7.1 ± 20.5 ml/m 2 ; p = 0.07 and LVEF +3.2 ± 8.0% vs. +2.4 ± 7.6%; p = 0.31). The absolute rate per 100 patient-years of the primary composite endpoint at 8 months tended to be lower in the vericiguat group (19.8) than the placebo group (29.6) (p = 0.07)., Conclusions: In this pre-specified echocardiographic study, significant improvements in LV structure and function occurred over 8 months in both vericiguat and placebo in a high-risk HFrEF population with recent worsening HF. Further studies are warranted to define the mechanisms of vericiguat's benefit in HFrEF., (© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Published
2023
Full Text
View/download PDF

37. The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019.

Author

Seferović PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinković I, Polovina M, Gale CP, Lund LH, Lopatin Y, Lainscak M, Savarese G, Huculeci R, Kazakiewicz D, and Coats AJS

Subjects
Europe epidemiology, Germany, Hospitalization, Humans, Cardiology, Heart Failure epidemiology, Heart Failure therapy
Abstract

Aims: The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) developed the HFA Atlas to provide a contemporary description of heart failure (HF) epidemiology, resources, reimbursement of guideline-directed medical therapy (GDMT) and activities of the National Heart Failure Societies (NHFS) in ESC member countries., Methods and Results: The HFA Atlas survey was conducted in 2018-2019 in 42 ESC countries. The quality and completeness of source data varied across countries. The median incidence of HF was 3.20 [interquartile range (IQR) 2.66-4.17] cases per 1000 person-years, ranging from ≤2 in Italy and Denmark to >6 in Germany. The median HF prevalence was 17.20 (IQR 14.30-21) cases per 1000 people, ranging from ≤12 in Greece and Spain to >30 in Lithuania and Germany. The median number of HF hospitalizations was 2671 (IQR 1771-4317) per million people annually, ranging from <1000 in Latvia and North Macedonia to >6000 in Romania, Germany and Norway. The median length of hospital stay for an admission with HF was 8.50 (IQR 7.38-10) days. Diagnostic and management resources for HF varied, with high-income ESC member countries having substantially more resources compared with middle-income countries. The median number of hospitals with dedicated HF centres was 1.16 (IQR 0.51-2.97) per million people, ranging from <0.10 in Russian Federation and Ukraine to >7 in Norway and Italy. Nearly all countries reported full or partial reimbursement of standard GDMT, except ivabradine and sacubitril/valsartan. Almost all countries reported having NHFS or working groups and nearly half had HF patient organizations., Conclusions: The first report from the HFA Atlas has shown considerable heterogeneity in HF disease burden, the resources available for its management and data quality across ESC member countries. The findings emphasize the need for a systematic approach to the capture of HF statistics so that inequalities and improvements in care may be quantified and addressed., (© 2021 European Society of Cardiology.)

Published
2021
Full Text
View/download PDF

38. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology.

Author

Jaarsma T, Hill L, Bayes-Genis A, La Rocca HB, Castiello T, Čelutkienė J, Marques-Sule E, Plymen CM, Piper SE, Riegel B, Rutten FH, Ben Gal T, Bauersachs J, Coats AJS, Chioncel O, Lopatin Y, Lund LH, Lainscak M, Moura B, Mullens W, Piepoli MF, Rosano G, Seferovic P, and Strömberg A

Subjects
Chronic Disease, Humans, Quality of Life, Self Care, Cardiology, Heart Failure
Abstract

Self-care is essential in the long-term management of chronic heart failure. Heart failure guidelines stress the importance of patient education on treatment adherence, lifestyle changes, symptom monitoring and adequate response to possible deterioration. Self-care is related to medical and person-centred outcomes in patients with heart failure such as better quality of life as well as lower mortality and readmission rates. Although guidelines give general direction for self-care advice, health care professionals working with patients with heart failure need more specific recommendations. The aim of the management recommendations in this paper is to provide practical advice for health professionals delivering care to patients with heart failure. Recommendations for nutrition, physical activity, medication adherence, psychological status, sleep, leisure and travel, smoking, immunization and preventing infections, symptom monitoring, and symptom management are consistent with information from guidelines, expert consensus documents, recent evidence and expert opinion., (© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Published
2021
Full Text
View/download PDF

39. Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure.

Author

Seferović PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, Bauersachs J, Anker SD, Ray R, Çavuşoğlu Y, Polovina M, Metra M, Ambrosio G, Prasad K, Seferović J, Jhund PS, Dattilo G, Čelutkiene J, Piepoli M, Moura B, Chioncel O, Ben Gal T, Heymans S, Jaarsma T, Hill L, Lopatin Y, Lyon AR, Ponikowski P, Lainščak M, Jankowska E, Mueller C, Cosentino F, Lund LH, Filippatos GS, Ruschitzka F, Coats AJS, and Rosano GMC

Subjects
Humans, Sodium-Glucose Transporter 2 metabolism, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 metabolism, Heart Failure drug therapy, Heart Failure metabolism, Sodium-Glucose Transporter 2 Inhibitors therapeutic use
Abstract

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given: • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus., (© 2020 European Society of Cardiology.)

Published
2020
Full Text
View/download PDF

40. Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document.

Author

Seferović PM, Piepoli MF, Lopatin Y, Jankowska E, Polovina M, Anguita-Sanchez M, Störk S, Lainščak M, Miličić D, Milinković I, Filippatos G, and Coats AJS

Subjects
Accreditation, Europe, Humans, Quality of Health Care, Cardiology, Heart Failure therapy
Abstract

Heart failure (HF) is the major contributor to cardiovascular morbidity and mortality. Given its rising prevalence, the costs of HF care can be expected to increase. Multidisciplinary management of HF can improve quality of care and survival. However, specialized HF programmes are not widely available in most European countries. These circumstances underlie the suggestion of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) for the development of quality of care centres (QCCs). These are defined as health care institutions that provide multidisciplinary HF management at all levels of care (primary, secondary and tertiary), are accredited by the HFA/ESC and are implemented into existing health care systems. Their major goals are to unify and improve the quality of HF care, and to promote collaboration in education and research activities. Three types of QCC are suggested: community QCCs (primary care facilities able to provide non-invasive assessment and optimal therapy); specialized QCCs (district hospitals with intensive care units, able to provide cardiac catheterization and device implantation services), and advanced QCCs (national reference centres able to deliver advanced and innovative HF care and research). QCC accreditation will require compliance with general and specific HFA/ESC accreditation standards. General requirements include confirmation of the centre's existence, commitment to QCC implementation, and collaboration with other QCCs. Specific requirements include validation of the centre's level of care, service portfolio, facilities and equipment, management, human resources, process measures, quality indicators and outcome measures. Audit and recertification at 4-6-year intervals are also required. The implementation of QCCs will evolve gradually, following a pilot phase in selected countries. The present document summarizes the definition, major goals, development, classification and crucial aspects of the accreditation process of the HFA/ESC QCC Programme., (© 2020 European Society of Cardiology.)

Published
2020
Full Text
View/download PDF

41. The Heart Failure Association Atlas: rationale, objectives, and methods.

Author

Seferović PM, Jankowska E, Coats AJS, Maggioni AP, Lopatin Y, Milinković I, Polovina M, Lainščak M, Timmis A, Huculeci R, and Vardas P

Subjects
Europe epidemiology, Humans, Cardiology, Heart Failure epidemiology, Heart Failure therapy
Abstract

Heart failure (HF) constitutes the growing cardiovascular burden and the major public health issue, but comprehensive statistics on HF epidemiology and related management in Europe are missing. The Heart Failure Association (HFA) Atlas has been initiated in 2016 in order to close this gap, representing the continuity directly rooted in the European Society of Cardiology (ESC) Atlas of Cardiology. The major aim of the HFA Atlas is to establish a contemporary dataset on HF epidemiology, resources and reimbursement policies for HF management, organization of the National Heart Failure Societies (NHFS) and their major activities, including education and HF awareness. These data are gathered in collaboration with the network of NHFS of the ESC member and ESC affiliated countries. The dataset will be continuously improved and advanced based on the experience and enhanced understanding of data collection in the forthcoming years. This will enable revealing trends, disparities and gaps in knowledge on epidemiology and management of HF. Such data are highly needed by the clinicians of different specialties (aside from cardiologists and cardiac surgeons), researchers, healthcare policy makers, as well as HF patients and their caregivers. It will also allow to map the snapshot of realities in HF care, as well as to provide insights for evidence-based health care policy in contemporary management of HF. Such data will support the ESC/HFA efforts to improve HF management ant outcomes through stronger recommendations and calls for action. This will likely influence the allocation of funds for the prevention, treatment, education and research in HF., (© 2020 European Society of Cardiology.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results